DirecTOR EARLY PHASE CLINICAL TRIALS (CANCER), Clinical Senior Lecturer, Imperial College London and Consultant Medical Oncologist, Imperial College NHS Healthcare Trust.
Dr Laura Kenny trained in Medicine in Queen's University Belfast, after completion of junior medical training she chose to persue a career in medical oncology. Following initial registrar training, she moved to London to study for a PhD in translational molecular imaging in the Cyclotron Building, Imperial College London. She was awarded a Westminster Medical School Oncology Trustee's fellowship.Her research focused on the use of novel PET radiotracers for studying proliferation (fluorothymidine (FLT)), angiogenesis (fluciclatide (AH-111585), and choline metabolism in breast cancer patients. Her work has been published in Cancer Research, Clinical Cancer Research, the Journal of Nuclear Medicine, and the European Journal of Molecular Imaging and Nuclear Medicine.
Laura was awarded a prestigious NIHR/MRC clinician scientist fellowship in 2010, the aim of her project was to establish new methods for defining the imaging phenotype in patients in vivo which will help predict drug resistance and drug sensitivity at early timepoints to established and novel cancer therapeutic agents. Her research has been recognised by the American Association of Cancer Research (Young Investigator Award), American Society of Clinical Oncology (Merit Award), British Cancer Research Meeting (Translational Research Award), and she also won the McElwain prize. Laura has been invited to give international lectures about her research.
More recently Laura was appointed as Director of Early Phase Clinical Trials in Cancer, where her aim is to expedite clinical drug development with novel approaches to clinical trials. She was also awarded an MRC DPFS project grant to study a new Affibody probe which will target her2 expression in breast cancer, this will be a first in man study and involves collaboration with 4 leading oncology centres in the UK. Her clinical practice is based at Charing Cross and Hammersmith Hospitals (part of Imperial College Healthcare NHS Trust).
et al., 2021, Comparison of two targeted ultra-deep sequencing technologies for analysis of plasma circulating tumour DNA in endocrine-therapy-resistant breast cancer patients, Breast Cancer Research and Treatment, Vol:188, ISSN:0167-6806, Pages:465-176
et al., 2022, A clinical study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced triple negative breast cancer (TNBC), San Antonio Breast Cancer Symposium, AMER ASSOC CANCER RESEARCH, ISSN:0008-5472
et al., 2021, Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR plus BC), Congress of the European-Society-for-Medical-Oncology (ESMO), ELSEVIER, Pages:S477-S478, ISSN:0923-7534
et al., 2021, First in human, modular study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced solid malignancies, Congress of the European-Society-for-Medical-Oncology (ESMO), ELSEVIER, Pages:S458-S458, ISSN:0923-7534
et al., 2021, Breast cancer treatment during the first wave of the COVID-19 pandemic at a UK centre, ESMO Breast Cancer Virtual Congress, ELSEVIER, Pages:S94-S94, ISSN:0923-7534